Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program

作者：Martino Massimo^*; Montanari Mauro; Bruno Benedetto; Console Giuseppe; Irrera Giuseppe; Messina Giuseppe; Offidani Massimo; Scortechini Ilaria; Moscato Tiziana; Fedele Roberta; Milone Giuseppe; Castagna Luca; Olivieri Attilio

来源：Expert Opinion on Biological Therapy, 2012, 12(11): 1449-1462.

DOI：10.1517/14712598.2012.707185

• autologous hemopoietic progenitor cell transplantation
• health care resources
• high-dose melphalan
• multiple myeloma
• outpatient
• waiting lists

Introduction: There are considerable concerns regarding the appropriate use of health care resources to reduce costs and waiting lists associated with autologous hematopoietic progenitor cell transplantation (AHPCT). One of the strategies to reach this goal is outpatient-based (OpB) AHPCT. %26lt;br%26gt;Areas covered: We reviewed all the reported experiences in this field and illustrated the various models of OpB AHPCT. %26lt;br%26gt;Expert opinion: The role of high-dose melphalan (HDM) followed by AHPCT in the treatment of Multiple Myeloma (MM) continues to evolve in the novel agent era and the International Myeloma Working Group recommends that AHPCT should be offered at some point in the course of the treatment program for a medically fit patient. The relatively short neutropenia and the limited extra-marrow toxicity after HDM support the hypothesis that MM patients are the most suitable for outpatient transplant programs. Various models have shown that the procedure is feasible and safe and may highly contribute to shorten waiting lists and to considerably cut health costs, with an improvement of quality of life. Ideal candidates may be those who are asymptomatic and fully active, who have a full-time caregiver and who can reside within easy reach from the transplant center.

• 出版日期2012-11